### Guideline Page and Request

**CSLL-D**  
**Internal request**  
Panel discussion request to reassess the inclusion of idelalisib + rituximab for relapsed/refractory CLL/SLL without del(17p)/TP53 mutation as a category 1 recommendation.

### Panel Discussion/References

The panel consensus was that idelalisib + rituximab for relapsed/refractory CLL/SLL without del(17p)/TP53 mutation should remain an option based on the available follow-up data regarding the efficacy (median progression-free survival) and safety. However, the panel consensus was to change the category of recommendation from a category 1 to a category 2A due to the increased risk for infections in patients with relapsed/refractory CLL.


### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>9</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>HT-3</td>
<td>Internal request</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|      | Panel discussion comment to include the following options for patients unable to receive chemoimmunotherapy with Richter’s transformation refractory to chemotherapy or in patients with a del(17p)/TP53 mutation:
|      | • nivolumab ± ibrutinib
|      | • pembrolizumab ± ibrutinib |

The panel consensus was that both regimens be included as options for patients unable to receive chemoimmunotherapy with Richter’s transformation refractory to chemotherapy or in patients with a del(17p)/TP53 mutation:

- nivolumab ± ibrutinib
- pembrolizumab ± ibrutinib

Nivolumab

Pembrolizumab